Join to View Full Profile
300 Mason Lord DriveKimmel Cancer CenterBaltimore, MD 21224
Phone+1 410-550-1711
Fax+1 410-550-1116
Dr. Forde is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2011 - 2014
Royal College of Surgeons IrelandClass of 2004
Certifications & Licensure
MD State Medical License 2014 - 2026
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
Clinical Trials
- Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Start of enrollment: 2015 Nov 23
- Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma Start of enrollment: 2017 Jun 13
- Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer Start of enrollment: 2017 Dec 12
- Join now to see all
Publications & Presentations
PubMed
- PD-L1 pfeRNAs as blood-based predictors of treatment response of unresectable malignant pleural mesothelioma patients administered Durvalumab with cisplatin and pemetr...Andrei Gurau, Suguru Yamauchi, Kaitlyn Ecoff, Kristen P Rodgers, James R Eshleman
Non-Coding RNA Research. 2025-06-01 - 1 citationsClinical development of immuno-oncology therapeutics.Jianxin Wang, Qi Chen, Qiang Shan, Tingbo Liang, Patrick Forde
Cancer Letters. 2025-05-01 - Higher levels of VEGF-A and TNFα in patients with immune checkpoint inhibitor-induced inflammatory arthritis.Elise F Gray-Gaillard, Ami A Shah, Clifton O Bingham Iii, Jennifer H Elisseeff, Joseph Murray
Arthritis Research & Therapy. 2025-04-01
Journal Articles
- Immuno-Oncology Trial Endpoints: Capturing Clinically Meaningful ActivityElad Sharon, Patrick M Forde, Valsamo Anagnostou, Hao Wang, Franco Verde, Mark Yarchoan, Clinical Cancer Research
Press Mentions
Year in Review: Non-Small Cell Lung CancerNovember 1st, 2024- Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLCSeptember 9th, 2024
- Exploratory Data Support Both Adjuvant and Neoadjuvant Nivolumab for NSCLCSeptember 9th, 2024
- Join now to see all
Professional Memberships
- Member
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/patrick-forde
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
